A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory TractFrancisco M. Marty, Sanjeet Dadwal, Polina German et al.|Clinical Infectious Diseases|2019Cited by 76
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant RecipientsRoy F. Chemaly, Michael Boeckh, Sudhakar Pipavath et al.|Clinical Infectious Diseases|2019Cited by 75
Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy RecipientsAlpana Waghmare, Zainab Shahid, Maheen Z. Abidi et al.|Biology of Blood and Marrow Transplantation|2020Cited by 65
Impacts of human mobility on the citywide transmission dynamics of 18 respiratory viruses in pre- and post-COVID-19 pandemic yearsAmanda C. Perofsky, Cécile Viboud, Helen Y. Chu et al.|Nature Communications|2024Cited by 51
Trends in Risk Factors and Symptoms Associated With SARS-CoV-2 and Rhinovirus Test Positivity in King County, Washington, June 2020 to July 2022C. Hansen, Cécile Viboud, Helen Y. Chu et al.|JAMA Network Open|2022Cited by 22